{
  "id": "f3e49b25e44ec1cb",
  "title": "Diamyd Medical accelerates primary efficacy readout by 9 months in type 1 diabetes Phase 3 trial following FDA alignment and guidance",
  "description": "20251229T094500Z",
  "content": "",
  "source": "prnewswire.com",
  "source_url": "http://www.prnewswire.com/news-releases/diamyd-medical-accelerates-primary-efficacy-readout-by-9-months-in-type-1-diabetes-phase-3-trial-following-fda-alignment-and-guidance-302650064.html",
  "published_at": "20251229T094500Z",
  "fetched_at": "2025-12-30T00:22:59.073919+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "fda"
  ],
  "location": "United States",
  "raw_data": {
    "url": "http://www.prnewswire.com/news-releases/diamyd-medical-accelerates-primary-efficacy-readout-by-9-months-in-type-1-diabetes-phase-3-trial-following-fda-alignment-and-guidance-302650064.html",
    "url_mobile": "",
    "title": "Diamyd Medical accelerates primary efficacy readout by 9 months in type 1 diabetes Phase 3 trial following FDA alignment and guidance",
    "seendate": "20251229T094500Z",
    "socialimage": "",
    "domain": "prnewswire.com",
    "language": "English",
    "sourcecountry": "United States"
  }
}